MT-101-101 trial for type 1 diabetes

Aim:

The trial treatment is designed to stop or reduce the immune attack on the pancreas that causes type 1 diabetes.

Initial studies confirmed its safety in individuals without type 1 diabetes; it now needs to be tested in those with type 1 diabetes. The results of this study will assist researchers to determine the optimal dose for future treatments with this drug.

Benefits:

Participants in this study will not receive any direct benefits. However, their involvement will contribute valuable scientific knowledge that may lead to new treatments for type 1 diabetes. The findings from this study could benefit others in the future. Participants in this trial will be compensated for their travel.

Participant requirements:

People with type 1 diabetes will receive up to three doses of the trial treatment through a vein in their arm at 29-day intervals. One dose will be a placebo (a dummy medication), and up to two doses will be the trial medication.

Participants will attend 15-18 visits to the clinical centre over six months.

The first visit (screening) will take up to 2 hours and include blood tests to assess eligibility. If eligible, participants will return to the clinic within 60 days for a visit that will take approximately 8 hours and include a Mixed-Meal Tolerance Test (MMTT) and the first dose of study treatment. Following visits will vary in length, with a further 1-2 long visits to receive study treatment

Site locations:

• Victoria – Royal Melbourne Hospital, Austin Health (CREDO), St Vincent’s Hospital
• NSW – AIM Diabetes Centre.

Participation criteria:

• People aged between 18 and 45 years
• Diagnosed with type 1 diabetes
• Currently using insulin (via injections or by pump)
• Living in Victoria or NSW

To find out more information and to register your interest, please click here or contact at atic@svi.edu.au / 03 9231 2480

This study has received ethical approval from the Alfred Hospital Ethics Committee:
HREC/107116-Alfred-2024